340B Drug Pricing Program

VNA Health Care President and CEO Linnea Windel Receives Silver Stevie® Award for Women in Business

Retrieved on:

Wednesday, December 6, 2023

Woman, 340B Drug Pricing Program, Gynaecology, Pediatrics, Patient, Obstetrics, School, VNA, Stevie Awards, Growth, Health care, Volunteering, CHC, Pharmacy, Nursing, Silver

AURORA, Ill., Dec. 6, 2023 /PRNewswire-PRWeb/ -- Linnea Windel, President and CEO of VNA Health Care, was recently awarded a Silver Stevie® Award for Woman of the Year – Healthcare at the 20th annual Stevie Awards for Women in Business. The Stevie Awards for Women in Business honor the achievements of women executives, entrepreneurs, employees, and the companies they run – worldwide. The Stevie Award has been hailed as the world's premier business award.

Key Points:

Linnea Windel, President and CEO of VNA Health Care, was recently awarded a Silver Stevie® Award for Woman of the Year – Healthcare at the 20th annual Stevie Awards for Women in Business.
AURORA, Ill., Dec. 6, 2023 /PRNewswire-PRWeb/ -- Linnea Windel, President and CEO of VNA Health Care , was recently awarded a Silver Stevie® Award for Woman of the Year – Healthcare at the 20th annual Stevie Awards for Women in Business.
The Stevie Awards for Women in Business honor the achievements of women executives, entrepreneurs, employees, and the companies they run – worldwide.
Linnea Windel, President and CEO of VNA Health Care, was recently awarded a Silver StevieⓇ Award for Woman of the Year – Healthcare at the 20th annual Stevie Awards for Women in Business.

Pacira BioSciences Reports Third Quarter 2023 Financial Results

Retrieved on:

Thursday, November 2, 2023

TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.

Key Points:

ET --
TAMPA, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the third quarter of 2023.
Total revenues were $163.9 million in the third quarter of 2023, versus $167.5 million reported for the third quarter of 2022.
Third quarter 2023 iovera° net product sales were $5.3 million, versus $4.5 million reported for the third quarter of 2022.
The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, November 2, 2023, at 8:30 a.m.

Pacira BioSciences Reports Second Quarter 2023 Financial Results

Retrieved on:

Wednesday, August 2, 2023

TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.

Key Points:

ET --
TAMPA, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2023.
Total revenues were $169.5 million in the second quarter of 2023, versus $169.4 million reported for the second quarter of 2022.
EXPAREL net product sales were $135.1 million in the second quarter of 2023, versus $137.0 million reported for the second quarter of 2022.
Second quarter 2023 iovera° net product sales were $4.4 million, versus $3.2 million reported for the second quarter of 2022.

Dr. Keri Kratofil to Become CEO of Care Resource

Retrieved on:

Thursday, July 6, 2023

Doctor of Pharmacy, Walgreens, University, Information technology, Pharmacy, 340B Drug Pricing Program, COVID-19, Head, Patient, Senior management, Growth, Health, Community, CPO, Management

MIAMI, July 6, 2023 /PRNewswire/ -- Care Resource's Board of Directors has identified Dr. Keri Kratofil to become the next Chief Executive Officer (CEO) of Care Resource Community Health Centers, Inc. Dr. Kratofil will transition first to Chief Operating Officer as of July 1, 2023, before assuming the role of Chief Executive Officer.

Key Points:

MIAMI, July 6, 2023 /PRNewswire/ -- Care Resource's Board of Directors has identified Dr. Keri Kratofil to become the next Chief Executive Officer (CEO) of Care Resource Community Health Centers, Inc. Dr. Kratofil will transition first to Chief Operating Officer as of July 1, 2023, before assuming the role of Chief Executive Officer.
Rick Siclari, current CEO of Care Resource, will work closely with her on a smooth transition.
Dr. Kratofil joined Care Resource's Senior Management team in early 2023 as the health center's Chief Pharmacy Offer (CPO) overseeing the expansion of pharmacy services and the 340b medications program.
Dr. Kratofil is an accomplished leader who possesses the foresight to build upon Rick Siclari's decades of success, propelling Care Resource into a new era of growth and innovation.

BioMatrix Specialty Pharmacy Welcomes Kathee Kramm to Executive Team

Retrieved on:

Tuesday, May 16, 2023

LDD, Nursing, Pharmacy, 340B Drug Pricing Program, Coagulopathy, Sale, Salembaree, Patient, CFO, Growth, Health, Biomatrix systems theory, Management

PLANTATION, Fla., May 16, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today Kathee Kramm has joined the executive leadership team as President and Chief Operating Officer. Working in collaboration with the CEO and CFO, Kathee will oversee sales, operations, nursing and revenue cycle management. She will play an integral role in BioMatrix's strategic priorities as a leader in the specialty infusion pharmacy industry.

Key Points:

PLANTATION, Fla., May 16, 2023 /PRNewswire/ -- BioMatrix Specialty Pharmacy announced today Kathee Kramm has joined the executive leadership team as President and Chief Operating Officer.
She will play an integral role in BioMatrix's strategic priorities as a leader in the specialty infusion pharmacy industry.
Ms. Kramm is an accomplished, entrepreneurial healthcare executive extensively experienced in specialty pharmacy and home infusion.
"We are excited to partner with Kathee and welcome her to our executive leadership team," CEO Nick Karalis affirms.

Pacira BioSciences Reports First Quarter 2023 Financial Results

Retrieved on:

Wednesday, May 3, 2023

TAMPA, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2023.

Key Points:

ET --
TAMPA, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2023.
First quarter 2023 iovera° net product sales were $4.0 million, versus $3.0 million reported for the first quarter of 2022.
First quarter royalty revenues were $0.9 million in the first quarter of 2023, versus $0.6 million reported for the first quarter of 2022.
The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Wednesday, May 3, 2023, at 8:30 a.m.

IntegriChain and Second Sight Solutions to Team up on 340B Issue Prevention for Pharma Manufacturers

Retrieved on:

Tuesday, April 18, 2023

Alliance for Telecommunications Industry Solutions, Second Sight, 340B Drug Pricing Program, Policy, Risk, Pharmaceutical industry, Pharma

"340B contract pharmacy arrangements have grown at an annual rate exceeding 25% over the past five years," said Second Sight Director Andrew Brownlee.

Key Points:

"340B contract pharmacy arrangements have grown at an annual rate exceeding 25% over the past five years," said Second Sight Director Andrew Brownlee.
We believe this initiative with IntegriChain will help serve the industry by streamlining the removal of ineligible rebates identified by the 340B ESP platform."
We are happy to partner with Second Sight on this important work for the Pharma industry."
As the first phase of this initiative, IntegriChain and Second Sight will plan to roll out the ICyte Script Management-340 ESP integration to participating pharmaceutical manufacturers in the third quarter of 2023.

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

Retrieved on:

Thursday, January 5, 2023

Bupivacaine, EBITDA, Therapy, Flexion Therapeutics, COVID-19, Acquisition, Growth, 340B Drug Pricing Program, Pharmaceutical industry, Animal, Lithium, Anatomical terms of motion

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.

Key Points:

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.
ZILRETTA net product sales of $28.0 million and $12.7 million for the fourth quarters of 2022 and 2021, respectively, and $9.4 million and $8.9 million for the months of December 2022 and 2021, respectively.
Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue, was $1.4 million and $1.8 million in the fourth quarters of 2022 and 2021 and $1.4 million and $0.7 million for the months of December 2022 and 2021, respectively.
Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue was $9.1 million in 2022, compared with $6.2 million in 2021.

AHF Opposes Creation of Splinter 340B Drug Discount Program

Retrieved on:

Wednesday, November 30, 2022

AIDS Healthcare Foundation ( AHF ) opposes the creation of a new drug discount program, 340C, for non-hospital community health providers.

Key Points:

AIDS Healthcare Foundation ( AHF ) opposes the creation of a new drug discount program, 340C, for non-hospital community health providers.
The push for the new federal program stems from unlawful efforts of drug companies to disable an already existing program, the 340B Drug Pricing Program , which has protected public health for 30 years.
Instead of aiding drug company priorities, 340B entities - which comprise the public health safety net in this country - must continue to work together to strengthen and protect the 340B program.
AHF urges 340B providers not to fall for the drug industrys divide-and-conquer trap, said Tom Myers, AHF General Counsel.

Therap Services interfaces with SuiteRx for its Pharmacy Interface module so that Individuals receive Direct Messages from Pharmacies that utilize the SRx: Pharmacy Management Software

Retrieved on:

Tuesday, October 11, 2022

Therap's Pharmacy Interface module is designed to provide a direct, secure communication platform, which is in compliance with HIPAA laws, for providers with pharmacies in HL7 format.

Key Points:

Therap's Pharmacy Interface module is designed to provide a direct, secure communication platform, which is in compliance with HIPAA laws, for providers with pharmacies in HL7 format.
Providers can use the Pharmacy Interface module to receive Direct Messages that contain medication and/or treatment information for an individual from a pharmacy.
The Pharmacy Interface module allows providers to receive messages from pharmacies that utilize Framework LTC, Genoa, LTC400, Proscript2000/Prodigy, QS/1-Primecare, Speedscript, and now SuiteRx.
Individuals in the pharmacy system need to be linked to individuals in the Therap system by the users in order to successfully receive Pharmacy Messages.